Compare Sana Biotechnology Inc (SANA) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Verisign, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Verisign, Inc. trades at $287 (market cap $25.51B). The key difference: Verisign, Inc. is far larger — about 24.8× Sana Biotechnology Inc's market cap, and Verisign, Inc. pays a 1.15% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VRSN | |
|---|---|---|
Market Cap | $1.03B | $25.51B |
Sector | Health | Technology |
52-Week High | $5.92 | $310.00 |
52-Week Low | $2.68 | $211.49 |
Enterprise Value | $946.04M | $26.82B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal but strong fundamentals including a 49.77% net income margin and record domain registrations. Recent Q2 2026 earnings beat estimates with EPS of $2.38, though Q4 2025 and Q2 2026 missed expectations. The stock faces headwinds from an antitrust lawsuit filed in September 2026, but institutional buying by firms like BlackRock signals confidence.
Outlook is mixed: bullish analyst consensus with a $328.50 price target suggests 16% upside, supported by AI-driven domain growth and a pending .web delegation. Risks include legal overhangs and competitive pressures. The current valuation at a P/E of 30.64 may limit near-term gains unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
